Recce Pharmaceuticals – equity proposition

Recce Pharmaceuticals is an innovative, late clinical-stage Australian biotech company focused on combating the global health crisis of antimicrobial resistance. The company is advancing a new class of synthetic anti-infective drugs to address critical unmet medical needs in infectious diseases, and it is close to commercialising its first product.

We highlight the key points of Recce Pharmaceuticals’ investment story.

1. Recce’s lead drug candidate, R327, uses a unique mechanism and is recognised by the WHO as the only anti-infective that disrupts ATP production.
2. Recce’s key targeted indications are areas that are not well served by existing drug treatments.
3. R327 has shown substantial antibacterial activity in a preclinical model for HAP/VAP against CRAB.
4. R327’s pipeline includes topical gel (diabetic foot infections, burn wound infections, ABSSSI) and IV (sepsis, cUTIs).
5. The topical gel is now nearing commercialisation for diabetic foot infections as a Phase III trial is underway.
6. Recce continues to benefit from support from international governments, reflecting the global need for novel anti-infectives.
7. The US DOW has awarded funding to support R327’s development for in-field use, including burn wound treatment.

If you would like to learn more about Recce Pharmaceuticals, please visit the Edison website.